OBJECTIVE: Oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycero-phosphorylcholine (Ox-PAPC) and its component phospholipid, 1-palmitoyl-2-(5,6 epoxyisoprostanoyl)-sn-glycero-3-phosphocholine (PEIPC), which are present in atherosclerotic lesions, activate endothelial cells to induce a complex inflammatory and pro-oxidant response. Previously, we demonstrated induction of genes regulating chemotaxis, sterol biosynthesis, the unfolded protein response, and redox homeostasis by Ox-PAPC in human aortic endothelial cells (HAECs). Activation of the c-Src kinase/signal transducer and activator of transcription 3 and the endothelial nitric oxide synthase/sterol regulatory element binding protein (SREBP) pathways were shown to regulate several of these inflammatory effects of Ox-PAPC in HAECs. The goal of the current studies was to determine the role of high-density lipoprotein (HDL) in regulating Ox-PAPC signaling in HAECs. METHODS AND RESULTS: Using quantitative real-time polymerase chain reaction, Western analysis, and functional studies, we demonstrated that pretreatment of HAECs with HDL reduced the induction of inflammatory, sterol biosynthetic, and unfolded protein response genes by Ox-PAPC and PEIPC; Ox-PAPC-induced chemotactic activity and monocyte binding were also decreased. These effects were associated with HDL inhibition of Ox-PAPC-induced c-Src, signal transducer and activator of transcription 3, and SREBP activation, alterations in endothelial nitric oxide synthase phosphorylation (previously associated with the inflammatory action of Ox-PAPC), and a decrease in superoxide formation. Finally, we demonstrated that treatment with HDL did not inhibit Ox-PAPC and PEIPC-induced activation of redox pathways, which protect the cell from the effects of oxidative stress. CONCLUSIONS: Taken together, these studies demonstrated that HDL inhibits the pro-inflammatory effects of Ox-PAPC and PEIPC, while maintaining the antioxidant activities of these lipids.
OBJECTIVE: Oxidized 1-palmitoyl-2-arachidonyl-sn-3-glycero-phosphorylcholine (Ox-PAPC) and its component phospholipid, 1-palmitoyl-2-(5,6 epoxyisoprostanoyl)-sn-glycero-3-phosphocholine (PEIPC), which are present in atherosclerotic lesions, activate endothelial cells to induce a complex inflammatory and pro-oxidant response. Previously, we demonstrated induction of genes regulating chemotaxis, sterol biosynthesis, the unfolded protein response, and redox homeostasis by Ox-PAPC in human aortic endothelial cells (HAECs). Activation of the c-Src kinase/signal transducer and activator of transcription 3 and the endothelial nitric oxide synthase/sterol regulatory element binding protein (SREBP) pathways were shown to regulate several of these inflammatory effects of Ox-PAPC in HAECs. The goal of the current studies was to determine the role of high-density lipoprotein (HDL) in regulating Ox-PAPC signaling in HAECs. METHODS AND RESULTS: Using quantitative real-time polymerase chain reaction, Western analysis, and functional studies, we demonstrated that pretreatment of HAECs with HDL reduced the induction of inflammatory, sterol biosynthetic, and unfolded protein response genes by Ox-PAPC and PEIPC; Ox-PAPC-induced chemotactic activity and monocyte binding were also decreased. These effects were associated with HDL inhibition of Ox-PAPC-induced c-Src, signal transducer and activator of transcription 3, and SREBP activation, alterations in endothelial nitric oxide synthase phosphorylation (previously associated with the inflammatory action of Ox-PAPC), and a decrease in superoxide formation. Finally, we demonstrated that treatment with HDL did not inhibit Ox-PAPC and PEIPC-induced activation of redox pathways, which protect the cell from the effects of oxidative stress. CONCLUSIONS: Taken together, these studies demonstrated that HDL inhibits the pro-inflammatory effects of Ox-PAPC and PEIPC, while maintaining the antioxidant activities of these lipids.
Authors: Sangderk Lee; Nima M Gharavi; Henry Honda; Irene Chang; Brandon Kim; Nelson Jen; Rongsong Li; Alejandro Zimman; Judith A Berliner Journal: Free Radic Biol Med Date: 2009-04-16 Impact factor: 7.376
Authors: Benjamin Emert; Yehudit Hasin-Brumshtein; James R Springstead; Ladan Vakili; Judith A Berliner; Aldons J Lusis Journal: J Lipid Res Date: 2014-05-23 Impact factor: 5.922
Authors: Piotr Ruchala; Mohamad Navab; Chun-Ling Jung; Susan Hama-Levy; Ewa D Micewicz; Hai Luong; Jonathan E Reyles; Shantanu Sharma; Alan J Waring; Alan M Fogelman; Robert I Lehrer Journal: PLoS One Date: 2010-04-14 Impact factor: 3.240
Authors: Fatiha Tabet; Kasey C Vickers; Luisa F Cuesta Torres; Carrie B Wiese; Bassem M Shoucri; Gilles Lambert; Claire Catherinet; Leonel Prado-Lourenco; Michael G Levin; Seth Thacker; Praveen Sethupathy; Philip J Barter; Alan T Remaley; Kerry-Anne Rye Journal: Nat Commun Date: 2014-02-28 Impact factor: 14.919
Authors: Mohamad Navab; Srinivasa T Reddy; Brian J Van Lenten; Georgette M Buga; Greg Hough; Alan C Wagner; Alan M Fogelman Journal: Arterioscler Thromb Vasc Biol Date: 2012-11 Impact factor: 8.311
Authors: Brian J Van Lenten; Alan C Wagner; Chun-Ling Jung; Piotr Ruchala; Alan J Waring; Robert I Lehrer; Andrew D Watson; Susan Hama; Mohamad Navab; G M Anantharamaiah; Alan M Fogelman Journal: J Lipid Res Date: 2008-07-11 Impact factor: 5.922